Free Trial

Cellectar Biosciences (CLRB) Competitors

Cellectar Biosciences logo
$4.50 -0.25 (-5.26%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$4.56 +0.06 (+1.33%)
As of 10/17/2025 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLRB vs. ALGS, ANL, ACRV, TLPH, HYPD, BRNS, QNTM, CELU, SKYE, and ELYM

Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Aligos Therapeutics (ALGS), Adlai Nortye (ANL), Acrivon Therapeutics (ACRV), Talphera (TLPH), Hyperion DeFi (HYPD), Barinthus Biotherapeutics (BRNS), Quantum Biopharma (QNTM), Celularity (CELU), Skye Bioscience (SKYE), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry.

Cellectar Biosciences vs. Its Competitors

Aligos Therapeutics (NASDAQ:ALGS) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Cellectar Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-2,337.24% -22.41% -12.09%
Cellectar Biosciences N/A -486.67%-150.57%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 4.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aligos Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Cellectar Biosciences has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$3.94M15.59-$131.21M-$19.79-0.50
Cellectar BiosciencesN/AN/A-$44.58M-$19.91-0.23

In the previous week, Aligos Therapeutics had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 4 mentions for Aligos Therapeutics and 2 mentions for Cellectar Biosciences. Aligos Therapeutics' average media sentiment score of 0.24 beat Cellectar Biosciences' score of -0.66 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aligos Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cellectar Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

Aligos Therapeutics presently has a consensus price target of $50.00, indicating a potential upside of 400.50%. Cellectar Biosciences has a consensus price target of $375.00, indicating a potential upside of 8,233.33%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Aligos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cellectar Biosciences
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Aligos Therapeutics beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLRB vs. The Competition

MetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$14.36M$11.04B$6.20B$10.55B
Dividend YieldN/A1.88%5.70%4.81%
P/E Ratio-0.2321.0385.7027.13
Price / SalesN/A26.44616.20134.69
Price / CashN/A24.5537.1060.81
Price / Book0.503.4112.236.52
Net Income-$44.58M$210.63M$3.33B$276.93M
7 Day Performance-3.02%0.03%1.17%1.93%
1 Month Performance-13.46%-0.54%6.85%2.19%
1 Year Performance-92.82%-9.78%58.93%34.62%

Cellectar Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLRB
Cellectar Biosciences
1.9613 of 5 stars
$4.50
-5.3%
$375.00
+8,233.3%
-92.8%$14.36MN/A-0.2310
ALGS
Aligos Therapeutics
3.8662 of 5 stars
$9.47
+0.4%
$50.00
+428.0%
+37.8%$58.01M$3.94M-0.4890News Coverage
High Trading Volume
ANL
Adlai Nortye
1.0615 of 5 stars
$1.64
+4.1%
$9.00
+450.5%
-14.6%$57.93M$5M0.00127Short Interest ↑
Gap Down
ACRV
Acrivon Therapeutics
2.7247 of 5 stars
$1.77
-3.3%
$15.00
+747.5%
-78.1%$57.56MN/A-0.7958Gap Up
TLPH
Talphera
2.4221 of 5 stars
$1.17
-4.9%
$5.00
+327.4%
-2.7%$56.07M$650K-2.9219News Coverage
Gap Up
HYPD
Hyperion DeFi
0.2673 of 5 stars
$7.78
-3.1%
$2.00
-74.3%
-84.1%$55.88M$60K-0.1340Gap Down
BRNS
Barinthus Biotherapeutics
2.1438 of 5 stars
$1.31
-3.7%
$3.00
+129.0%
+8.3%$55.38M$14.97M-0.76107Analyst Forecast
Short Interest ↑
Gap Down
QNTM
Quantum Biopharma
0.218 of 5 stars
$15.19
+4.7%
N/A+87.5%$55.37MN/A-1.08N/AGap Down
CELU
Celularity
2.6567 of 5 stars
$2.04
-0.5%
$6.00
+194.1%
-21.1%$54.72M$54.22M-0.64220Short Interest ↓
SKYE
Skye Bioscience
2.3649 of 5 stars
$1.51
-13.0%
$9.80
+551.2%
-70.2%$53.61MN/A-1.4211
ELYM
Eliem Therapeutics
N/A$1.80
-4.8%
N/A-60.3%$53.55MN/A-3.409

Related Companies and Tools


This page (NASDAQ:CLRB) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners